New drug hope for Tough-to-Treat throat cancer

NCT ID NCT06118333

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced nasopharyngeal cancer that has not responded to at least two prior treatments. About 386 participants will be randomly assigned to receive either the new drug or a standard chemo chosen by their doctor. The main goals are to see if the new drug shrinks tumors and helps people live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (a drug given by IV)
What this could lead to: If it works, this could offer a new treatment option for people with advanced nasopharyngeal cancer who have run out of standard therapies.
What could go wrong: This is a late-stage trial, but the drug is still experimental. It may not work better than existing chemo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.